Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients.
M2 PHARMA-October 23, 2018-Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients
(C)2018 M2 COMMUNICATIONS
A phase III trial has indicated that Lynparza maintenance therapy decreased risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated (BRACm) ovarian cancer, it was reported on Monday.
The Phase III SOLO-one trial evaluated the product as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial response following first-line standard platinum-based chemotherapy. The study indicated statistically-significant and clinically-meaningful improvement in progression-free survival for Lynparza compared with placebo and reduced the risk of disease progression or death by 70%.
The product is being jointly developed and commercialised by AstraZeneca and Merck. At present, Lynparza secured approval in more than 60 countries to treat platinum-sensitive relapsed ovarian cancer regardless of BRCA status.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 23, 2018|
|Previous Article:||Vertex Pharmaceuticals (Europe) receives positive opinion from European watchdog for Kalydeco.|
|Next Article:||Teva Formalises North America Headquarters Move with Ceremony in Israel.|